Valuation
- Market cap
- 89,630,000
- Revenue TTM
- $0
- Net income TTM
- $-104,080,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 663,700
- Avg volume
- 1,114,088
- Day's range
- $1.12 – $1.21
- Shares out
- 71,704,000
- Stochastic %K
- 6%
- Beta
- 1.24
- Analysts
- Strong Buy
- Price target
- $10.50
Company profile
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutro...
Show more
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 925 407 1049
- Website
- https://www.nkartatx.com
- Address
- 1150 Veterans Boulevard, South San Francisco, United States
Latest news
No headlines yet.